Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Lars Erik Kristensen, Atul Deodhar, Ying-Ying Leung, Ivana Vranic, Mahta Mortezavi, Lara Fallon, Arne Yndestad, Cassandra D Kinch, Dafna D Gladman
In this commentary, we review clinical data which helps inform individualized benefit-risk assessment for tofacitinib in patients with psoriatic arthritis (PsA) and ankylosing spondylitis (AS). ORAL Surveillance, a safety trial of patients ≥ 50 years of age with rheumatoid arthritis (RA) and cardiovascular risk factors, found increased rates of safety outcomes (including major adverse cardiovascular events [MACE], malignancies excluding non-melanoma skin cancer, and venous thromboembolism) with tofacitinib versus tumor necrosis factor inhibitors (TNFi)...
May 2, 2024: Rheumatology and Therapy
#2
REVIEW
Himanshu Arora, Binish Javed, L V Simhachalam Kutikuppala, Mayuri Chaurasia, Kaarvi Khullar, Shreevikaa Kannan, Varshitha Golla
Interleukin-33 (IL-33), belonging to the interleukin-1 cytokine family, has a decoy receptor soluble ST2 (sST2). IL-33 is found in oligodendrocytes and astrocytes and is involved in central nervous system healing and repair, whereas ST2 is found in microglia and astrocytes. Some studies have found a link between changes in the IL-33/ST2 pathway and neurodegenerative disorders. This review article investigates the relationship between the interleukin-33 (IL-33)/ST2 pathway and neurodegenerative disorders. It was discovered that soluble st2 levels were increased...
May 2024: Annals of Medicine and Surgery
#3
JOURNAL ARTICLE
Gerd R Burmester, Jayne Stigler, Andrea Rubbert-Roth, Yoshiya Tanaka, Valderilio F Azevedo, Derek Coombs, Ivan Lagunes, Ralph Lippe, Peter Wung, Lianne S Gensler
INTRODUCTION: This integrated analysis of the phase 2/3 and phase 3 SELECT trials describes the safety profile of upadacitinib, an oral Janus kinase inhibitor, for up to 5 years of exposure across psoriatic arthritis (PsA), ankylosing spondylitis (AS), and non-radiographic axial spondyloarthritis (nr-axSpA) (including pooled axial spondyloarthritis [axSpA]). METHODS: Safety data from five trials of upadacitinib in PsA (2 trials), AS (2 trials), and nr-axSpA (1 trial) were analyzed up to a data cut-off of August 15, 2022...
April 29, 2024: Rheumatology and Therapy
#4
JOURNAL ARTICLE
Consuelo Romero-Sánchez, Carlos Ferrer-Santos, Deisy Abril, Eduin Acosta-Hernández, Juliette De Ávila, Alejandro Ramos-Casallas, Javier Escobar, Wilson Bautista-Molano, Diego Jaimes, Adriana Beltrán-Ostos, Juan Manuel Bello-Gualtero, Cristian Flórez-Sarmiento, Viviana Parra-Izquierdo, Omar Javier Calixto
OBJECTIVE: To compare the diversity and composition of the gastrointestinal microbiome of patients with SpA. METHODS: MiSeq sequencing of the V3-V4 region of the 16S ribosomal RNA gene was performed on DNA isolated from stool. Patients with concurrent SpA and IBD were excluded. Differences were assessed for richness and diversity indices by QIIME 2™. Differences between means >0,2% with a p-value<0,05 were assumed significant. Institutional Ethics Committee endorsement...
February 1, 2024: Revista Alergia Mexico: Organo Oficial de la Sociedad Mexicana de Alergia e Inmunología, A.C
#5
REVIEW
Raymond Osayamen Schaefer, Niklas Rutsch, Klaus J Schnake, Mohamed M Aly, Gaston Camino-Willhuber, Martin Holas, Ulrich Spiegl, Sander Muijs, Christoph E Albers, Sebastian F Bigdon
Injuries to the rigid spine have a distinguished position in the broad spectrum of spinal injuries due to altered biomechanical properties. The rigid spine is more prone to fractures. Two ossification bone disorders that are of particular interest are Ankylosing Spondylitis (AS) and Diffuse Idiopathic Skeletal Hyperostosis (DISH). DISH is a non-inflammatory condition that leads to an anterolateral ossification of the spine. AS on the other hand is a chronic inflammatory disease that leads to cortical bone erosions and spinal ossifications...
2024: Brain Spine
#6
MULTICENTER STUDY
Gustavo Gomes Resende, Carla Goncalves Schahin Saad, Claudia Diniz Lopes Marques, Sandra Lúcia Euzébio Ribeiro, Maria Bernadete Renoldi de Oliveira Gavi, Michel Alexandre Yazbek, Adriana de Oliveira Marinho, Rita de Cássia Menin, Manuella Lima Gomes Ochtrop, Andressa Miozzo Soares, Nara Gualberto Cavalcanti, Jamille Nascimento Carneiro, Glaucio Ricardo Werner de Castro, José Mauro Carneiro Fernandes, Elziane da Cruz Ribeiro E Souza, Corina Quental de Menezes Alvarenga, Rejane Maria Rodrigues de Abreu Vieira, Natalia Pereira Machado, Antônio Carlos Ximenes, Morgana Ohira Gazzeta, Cleandro Pires de Albuquerque, Thelma Larocca Skare, Mauro Waldemar Keiserman, Charles Lubianca Kohem, Gabriel Sarkis Benacon, Vítor Florêncio Santos Rocha, Ricardo da Cruz Lage, Olivio Brito Malheiro, Rywka Tenenbaum Medeiros Golebiovski, Thauana Luiza Oliveira, Ruben Horst Duque, Ana Carolina Londe, Marcelo de Medeiros Pinheiro, Percival Degrava Sampaio-Barros
BACKGROUND: There is a remarkable variability in the frequency of HLA-B27 positivity in patients with spondyloarthritis (SpA), which may be associated with different clinical presentations worldwide. However, there is a lack of data considering ethnicity and sex on the evaluation of the main clinical and prognostic outcomes in mixed-race populations. The aim of this study was to evaluate the frequency of HLA-B27 and its correlation with disease parameters in a large population of patients from the Brazilian Registry of Spondyloarthritis (RBE)...
April 26, 2024: Advances in Rheumatology
#7
JOURNAL ARTICLE
Aspergillus Endogenous Endophthalmitis as a Clue to Identifying a Delayed Lumbosacral Osteomyelitis.
Muhammed Altinisik, Yeliz Delibay Akgun, Mustafa Erdogan, Azzam Faiz Mutawakkil, Horu Gazi
PURPOSE: To present a case of aspergillus-induced endogenous endophthalmitis evolving into delayed lumbosacral osteomyelitis, initially misdiagnosed as ankylosing spondylitis (AS) in an immunocompetent patient. METHOD: Case Report. RESULTS: A 38-year-old woman, initially treated for pneumonia, experienced sudden loss of vision in her left eye, prompting a thorough examination that revealed a distinct chorioretinal infiltrate. Microbiological analysis of the patient's vitreous samples detected Aspergillus fumigatus, leading to the diagnosis of endogenous endophthalmitis...
April 26, 2024: Ocular Immunology and Inflammation
#8
JOURNAL ARTICLE
Seulkee Lee, Seonyoung Kang, Hyungjin Kim, Jaejoon Lee, Min-Ji Kim, Hoon-Suk Cha
BACKGROUND: We aimed to investigate whether there are sex differences in disease activity measures among patients with axial spondyloarthritis (axSpA) and to determine any potential impact on the assessment of treatment responses to tumor necrosis factor alpha inhibitors (TNFi). METHODS: Using the Korean College of Rheumatology Biologics and Targeted Therapy (KOBIO) registry data, we compared sex differences in changes in the Bath Ankylosing Spondylitis Disease Activity Score (BASDAI) and Ankylosing Spondylitis Disease Activity Score (ASDAS) levels at baseline and one year after TNFi initiation in patients with axSpA...
April 25, 2024: Arthritis Research & Therapy
#9
REVIEW
Ji Li, Shiyu Wang, Xiao-Dong Li, Yang Han
Generalized pustular psoriasis (GPP) is characterized by painful and occasionally disfiguring cutaneous manifestations with sepsis-like systemic symptoms, and is a rare severe variant of psoriasis. Currently, there is no standard treatment for GPP. Here, we report a case of a female patient with ankylosing spondylitis (AS) and mild scalp psoriasis, who developed GPP and alopecia following three courses of adalimumab therapy. The patient's condition gradually improved following cessation of adalimumab and treatment with secukinumab and acitretin...
April 2024: Journal of International Medical Research
#10
JOURNAL ARTICLE
Anna Sheahan, Suzanne Anjohrin, Robert Suruki, Jeffrey L Stark, Victor S Sloan
OBJECTIVE: To describe patients' use of opioids in the year preceding and year following new diagnosis of ankylosing spondylitis (AS), psoriatic arthritis (PsA), or rheumatoid arthritis (RA), compared with patients without the/se diseases. METHODS: This study used US IBM® MarketScan® Commercial Claims and Encounters (CCAE) and Medicaid data and included three cohorts, comprised of incident cases of AS, PsA, or RA (2010-2017). Three matched comparator patients (without the incident disease) were selected for each patient within the disease cohort...
April 25, 2024: Clinical Rheumatology
#11
Mustafa Kayabaşı, Turhan Mammadov, Seher Köksaldı, Gül Arıkan, Süleyman Kaynak, Ali Osman Saatci
Toxoplasma chorioretinitis (TC) can exhibit atypical features in immunocompromised patients including bilaterality, extensive spread, multifocal presentation, large areas of retinal necrosis without adjacent retinal scarring, and diffuse necrotizing retinitis resembling the viral retinitis that may cause confusion in the differential diagnosis. The aim of this study was to present the clinical features of four eyes of three immunocompromised patients with active toxoplasma chorioretinitis. Two of the patients were female and one, male...
2024: Archive of clinical cases
#12
JOURNAL ARTICLE
Michael F Mørup, Vanessa Taieb, Damon Willems, Micah Rose, Nikos Lyris, Mark Lamotte, Laetitia Gerlier, Howard Thom
AIMS: To estimate the cost-effectiveness of a treatment-pathway initiated with bimekizumab, a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A, in patients with axial spondyloarthritis (axSpA) compared with IL-17A inhibitors, ixekizumab, and secukinumab, from the National Health Service (NHS) of Scotland perspective. METHODS: The axSpA treatment-pathway was modeled using a one-year decision tree followed by a lifetime Markov model...
April 23, 2024: Journal of Medical Economics
#13
JOURNAL ARTICLE
Kurt de Vlam, Walter P Maksymowych, Gaia Gallo, Proton Rahman, Philip Mease, Venkatesh Krishnan, Conor J McVeigh, Jeffrey Lisse, Danting Zhu, Rebecca J Bolce, Philip G Conaghan
INTRODUCTION: The objective of this analysis is to evaluate the improvement in spinal pain with ixekizumab, placebo, and adalimumab based on objective measures of inflammation response in patients with ankylosing spondylitis (AS). METHODS: The COAST-V 52-week, double-blind, placebo-controlled, randomized phase III trial examined the efficacy of ixekizumab in patients with active AS; adalimumab was used as an active reference arm. Treatment effects on reduction in pain were assessed by objective measures of controlled and persisting inflammation (defined by magnetic resonance imaging [MRI], C-reactive protein [CRP], or MRI + CRP status)...
April 18, 2024: Rheumatology and Therapy
#14
JOURNAL ARTICLE
Letícia R Morimoto, Daisy T Kase, Paola G Esmanhotto, Murilo A Maciel, Ana C L Augusto, Patrick F Catricala, Julia E C Anaya, Sugoto Mukherjee, Artur R C Fernandes, André Y Aihara
Nontraumatic pathologic conditions of the craniovertebral junction encompass a range of conditions affecting the complex anatomy of this region without direct physical injury. These conditions include congenital syndromes that predispose individuals to ligamentous laxity, potentially leading to instability. Additionally, rare but noteworthy cases such as Grisel syndrome, a cause of pediatric torticollis, may arise without a traumatic trigger. Inflammatory diseases, including rheumatoid arthritis, ankylosing spondylitis, and crystal deposition, can lead to cervical instability and spinal cord compression...
May 2024: Radiographics: a Review Publication of the Radiological Society of North America, Inc
#15
Ashkon Nehzati, Donald Hefelfinger, Elizabeth Fonte, Joshua Scott
Musculoskeletal coccidioidomycosis is a rare disseminated fungal infection caused by either Coccidioides immitis or Coccidioides posadasii endemic to the southwestern United States and northwestern Mexico, as well as Guatemala, Brazil, and other locations in Central and South America. Symptomatic primary infection of coccidioidomycosis can present as pneumonia with influenza-like symptoms, but the majority of cases remain asymptomatic. When dissemination occurs, the most common extrapulmonary sites include the skin, lymph nodes, musculoskeletal system, and meninges...
March 2024: Curēus
#16
JOURNAL ARTICLE
Kassem Sharif, Adi Lahat, Yonatan Shneor Patt, Niv Ben-Shabat, Mahmud Omar, Abdulla Watad, Howard Amital, Omer Gendelman
BACKGROUND: Ankylosing spondylitis (AS) and inflammatory bowel disease (IBD) are chronic conditions with overlapping pathogenic mechanisms. The genetic predisposition and inflammatory pathways common to both diseases suggest a syndemic relationship. While some evidence points to a connection between the two conditions, other reports do not support this link. OBJECTIVES: To investigate the association between AS and the subsequent incidence of IBD. To identify potential risk factors and effect modifiers that contribute to this relationship...
April 2024: Israel Medical Association Journal: IMAJ
#17
JOURNAL ARTICLE
Carmen Priego-Pérez, María Ángeles Puche-Larrubia, Lourdes Ladehesa-Pineda, Jerusalem Calvo-Guitérrez, Rafaela Ortega-Castro, Alejandro Escudero-Contreras, Nuria Barbarroja, Eduardo Collantes-Estévez, Clementina López-Medina
Background : The objectives were as follows: (a) to identify, among patients with axial spondyloarthritis (axSpA), "clusters" of patients based on the presence of peripheral and extra-musculoskeletal manifestations (EMMs) and (b) to compare the effectiveness of the first anti-TNF drugs across the different clusters after 6 months of follow-up. Methods: An observational and retrospective study of 90 axSpA patients naïve to bDMARDs was conducted. An unsupervised cluster analysis using the "k-means" technique was performed using variables of peripheral and EMMs...
March 23, 2024: Journal of Clinical Medicine
#18
JOURNAL ARTICLE
Shuai Zhang, Wenjun Hao, Dongying Chen, Siwen Chen, Zihao Li, Fangling Zhong, Haitao Wang, Jianru Wang, Zhaomin Zheng, Zhongping Zhan, Guo Dai, Hui Liu
OBJECTIVE: To investigate the effect of intermittent parathyroid hormone (iPTH) administration on pathological new bone formation during treatment of ankylosing spondylitis-related osteoporosis. METHODS: Animal models with pathological bone formation caused by hypothetical AS pathogenesis received treatment with iPTH. We determined the effects of iPTH on bone loss and the formation of pathological new bone with micro-computed tomography (micro-CT) and histological examination...
April 4, 2024: Biochemical and Biophysical Research Communications
#19
RANDOMIZED CONTROLLED TRIAL
Victoria Navarro-Compán, Sofia Ramiro, Atul Deodhar, Philip J Mease, Martin Rudwaleit, Christine de la Loge, Carmen Fleurinck, Vanessa Taieb, Michael F Mørup, Ute Massow, Jonathan Kay, Marina Magrey
OBJECTIVE: To assess how achievement of increasingly stringent clinical response criteria and disease activity states at week 52 translate into changes in core domains in patients with non-radiographic (nr-) and radiographic (r-) axial spondyloarthritis (axSpA). METHODS: Patients in BE MOBILE 1 and 2 achieving different levels of response or disease activity (Assessment of SpondyloArthritis International Society (ASAS) and Ankylosing Spondylitis Disease Activity Score (ASDAS) response criteria, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI50)) at week 52 were pooled, regardless of treatment arm...
April 10, 2024: RMD Open
#20
JOURNAL ARTICLE
Ji-Won Kim, Jun Sik Yoon, Sojeong Park, Hasung Kim, Ji Sung Lee, Jung-Yoon Choe
OBJECTIVE: To investigate the risk of cardiovascular disease (CVD) associated with increasing dose of a non-steroidal anti-inflammatory drug (NSAID) in patients with ankylosing spondylitis (AS). METHODS: Using the Korean National Health Insurance database, patients newly diagnosed with AS without prior CVD between 2010 and 2018 were included in this nationwide cohort study. The primary outcome was CVD, a composite outcome of ischaemic heart disease, stroke or congestive heart failure...
April 9, 2024: Annals of the Rheumatic Diseases
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
